Sheena Jonathan sold $479K of NTRA (indirect holdings)
Sheena Jonathan sold 1,500 indirectly-held shares of Natera, Inc. (NTRA) at an average of $319.30 ($315.26–$324.76, $0.48M total) across 14 trades on 2026-11-11 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The director's sale reduces insider ownership, which may be interpreted as a weak signal by traders, but the modest size limits material impact.
Market read
Provides fresh insider‑sale data; relevance is limited to short‑term price pressure considerations.
What to watch
Potential upcoming corporate developments or earnings that may offset any short‑term pressure.
Background
SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.
Ticker impact
Director Sheena Jonathan sold $479K of Natera shares via a 10b5-1 plan, reducing her holdings to 7,500 shares.
potential slight downside as market prices in the director's sale
Sale size is modest ($479K) and executed under a pre‑arranged plan, so impact is likely limited but could nudge the stock lower.
Market effects
Minimal; the sale does not affect the broader genetic‑testing sector.
None; the transaction is company‑specific.
Low; no broader market impact expected.
Counterpoint
The sale could be routine under a 10b5‑1 plan and not indicative of future performance.
Key entities
- companyNatera, Inc.
Genetic testing and diagnostics firm listed on NASDAQ (NTRA).
- personSheena Jonathan
Director of Natera who sold shares under a 10b5‑1 plan.



